Health Care [ 4/12 ] | Health Care Providers & Services [ 28/72 ]
NYSE | Common Stock
Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide.
The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents.
The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry.
It markets its products and services through its direct sales force and a network of distributors.
The company was incorporated in 1976 and is headquartered in Farmingdale, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 13, 24 | -0.06 Increased by +74.35% | - |
| Mar 13, 24 | -0.06 Increased by +72.24% | - |
| Nov 3, 23 | -0.13 Increased by +22.47% | - |
| Jun 14, 23 | -0.31 Decreased by -207.50% | - |
| Mar 20, 23 | -0.23 Decreased by -360.00% | - |
| Dec 12, 22 | -0.22 Decreased by -336.60% | - |
| Oct 14, 22 | -0.17 Decreased by -342.86% | - |
| Jun 9, 22 | -0.10 Decreased by -350.00% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Oct 31, 23 | -19.66 M Decreased by -207.57% | 57.43 M Increased by +562.10% | Decreased by -292.12% Decreased by -329.57% |
| Jul 31, 23 | 31.06 M Increased by +53.13% | 20.29 M Increased by +1.14 K% | Increased by +65.32% Increased by +710.33% |
| Apr 30, 23 | 16.11 M Decreased by -38.57% | -14.73 M Decreased by -62.90% | Decreased by -91.44% Decreased by -165.19% |
| Jan 31, 23 | 16.34 M Decreased by -52.01% | -10.66 M Decreased by -301.36% | Decreased by -65.22% Decreased by -736.37% |
| Oct 31, 22 | 18.28 M Decreased by -31.08% | -12.43 M Decreased by -435.92% | Decreased by -68.00% Decreased by -677.64% |
| Jul 31, 22 | 20.28 M Decreased by -18.25% | 1.64 M Decreased by -49.97% | Increased by +8.06% Decreased by -38.80% |
| Apr 30, 22 | 26.22 M Decreased by -20.05% | -9.04 M Decreased by -550.75% | Decreased by -34.48% Decreased by -663.77% |
| Jan 31, 22 | 34.05 M Increased by +8.20% | -2.65 M Decreased by -215.33% | Decreased by -7.80% Decreased by -206.59% |